RESUMEN
A range of wound dressings currently available in the UK and elsewhere, each claiming to possess different performance characteristics, can make dressing selection difficult. This report concentrates on the superabsorbent polymer dressings (SAPs) - which are designed to absorb medium to high levels of exudate and to maintain an 'ideal moist wound healing environment'. What do these dressings achieve, what are they suitable/not suitable for, and are all super-absorbent dressings equal in terms of performance and quality? When assessing the key performance characteristics of absorbency, moisture vapour transmission rate (MVTR), strikethrough and structural integrity, results show that SAPs are not all the same-in fact each of them varies considerably and may lend themselves to different wound aetiologies and usage conditions. While performance data is often presented from non-standard tests or modifications, it is proposed that to provide clarity over dressing selection, all SAPs were measured using International Standards for the key performance characteristics. This will aid clinical staff in selecting the most appropriate dressing for each wound.
Asunto(s)
Vendajes/normas , Exudados y Transudados/fisiología , Cicatrización de Heridas/fisiología , Heridas y Lesiones/terapia , Almohadillas Absorbentes , Estudios de Evaluación como Asunto , Humanos , Reino UnidoRESUMEN
OBJECTIVE: To demonstrate the binding and inactivation action of a superabsorbent dressing on proteolytic enzymes MMP-2, MMP-9 and collagenase using an established methodology. METHOD: An in vitro assay of MMP binding and collagenase inactivation has been conducted using the superabsorbent wound dressing (Eclypse; Advancis Medical UK). Dressings in this category, and other absorbents, have been claimed to possess MMP-binding characteristics; however, for most there is no published evidence as yet. In this series of experiments, we have used validated experimental techniques to evaluate such activity. RESULTS: Results show that the superabsorbent dressing does have a statistically-significant effect in binding two of the most important MMPs, MMP-2 and MMP-9, as well as inhibiting collagenase. CONCLUSION: These results support this activity for the superabsorbent dressing and indicate a probable beneficial clinical action in reducing the influence of these enzymes in delayed wound healing.
Asunto(s)
Vendajes , Colagenasas/metabolismo , Exudados y Transudados/enzimología , Metaloproteinasa 2 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/metabolismo , Heridas y Lesiones/terapia , Absorción , Células Cultivadas , Humanos , Ensayo de Materiales , Unión Proteica , Heridas y Lesiones/enzimologíaRESUMEN
The focus on quality of life issues in wound care has justly taken a far greater importance. With the acceptance that pain can be a major factor to the patient, and in particular, pain at dressing change comes the opportunity for avoidance and/or reduction strategies. Whilst pain has been associated with wound infection for millennia, it is only much more recently that this has received due attention from research and clinical practice. In this study, the nature of pain, changes in pain and pain associated with infection are the focal points. A Delphi approach, now a frequently used tool in wound care research, has been used to obtain expert opinion on these aspects of management.
Asunto(s)
Vendajes , Manejo del Dolor , Dolor/etiología , Calidad de Vida , Infección de Heridas/complicaciones , Infección de Heridas/terapia , Administración Tópica , Analgésicos/uso terapéutico , Antibacterianos/administración & dosificación , Vendajes/efectos adversos , Enfermedad Crónica , Técnica Delphi , Humanos , Pautas de la Práctica en Enfermería , Pautas de la Práctica en Medicina , Cicatrización de Heridas , Infección de Heridas/diagnósticoAsunto(s)
Antiinfecciosos Locales/administración & dosificación , Vendajes , Sulfadiazina de Plata/administración & dosificación , Heridas y Lesiones/tratamiento farmacológico , Heridas y Lesiones/enfermería , Administración Tópica , Antiinfecciosos Locales/efectos adversos , Infecciones Bacterianas/enfermería , Infecciones Bacterianas/prevención & control , Niño , Humanos , Enfermería Pediátrica/métodos , Sulfadiazina de Plata/efectos adversosRESUMEN
Wound care practice continuously demonstrates that healing cannot be adequately controlled if a patient's experience of pain is not managed effectively. Current pain management guidelines do not account for the holistic treatment of pain emanating from a wound-an environment of uncontrolled or rogue inflammation, neuropathy and neuroischaemia. This article investigates how polymeric membrane dressings can interact with the pathology of wounds to correct abnormalities in pain pathways of the nervous system and dampen problematic ongoing pain to enhance the clinical picture of wound healing.
Asunto(s)
Vendajes , Salud Holística , Dolor/prevención & control , Heridas y Lesiones/terapia , Disnea , Humanos , Dolor/etiología , Autocuidado , Resultado del Tratamiento , Cicatrización de Heridas , Heridas y Lesiones/complicacionesAsunto(s)
Plata/uso terapéutico , Cuidados de la Piel , Heridas y Lesiones/terapia , Vendajes , Preescolar , Humanos , Lactante , Recién NacidoRESUMEN
Pulmonary arterial hypertension (PAH) is an enigmatic, often fatal disease of the lung. Excess vasoconstriction and progressive obliteration of the precapillary arterioles combine to reduce the cross-sectional area for blood flow and thus cause chronic elevation in the pulmonary arterial pressures with progressive right heart dysfunction, heart failure and death. In 1995, the FDA approved the first therapy for PAH: epoprostenol, a highly efficacious drug but one that was difficult to use for patients and clinicians alike. Since then, there have been eight additional drugs approved, each offering advantages in terms of convenience over previously available drugs. In 2009, tadalafil (Adcirca®) was approved for PAH. The 405 patients enrolled in the single pivotal trial give this drug the largest initial placebo-controlled dataset of any of the oral PAH therapies; its once-daily dosing and excellent safety profile make it the most convenient of the therapies by a significant margin. After introducing the PAH disease state with references for more interested readers, this paper discusses the nitric oxide pathway as it relates to the pulmonary circulation, provides an overview of clinically available phosphodiesterase inhibitors and discusses tadalafil in relationship to sildenafil (Revatio®), the first phosphodiesterase inhibitor approved for PAH.
Asunto(s)
Antihipertensivos/uso terapéutico , Carbolinas/uso terapéutico , Inhibidores de Fosfodiesterasa 5/uso terapéutico , Vasodilatadores/uso terapéutico , Animales , Antihipertensivos/efectos adversos , Antihipertensivos/farmacocinética , Presión Sanguínea/efectos de los fármacos , Carbolinas/efectos adversos , Hipertensión Pulmonar Primaria Familiar , Humanos , Hipertensión Pulmonar/tratamiento farmacológico , Hipertensión Pulmonar/metabolismo , Hipertensión Pulmonar/fisiopatología , Riñón/fisiopatología , Óxido Nítrico/metabolismo , Inhibidores de Fosfodiesterasa 5/efectos adversos , Inhibidores de Fosfodiesterasa 5/farmacocinética , Piperazinas/uso terapéutico , Purinas/uso terapéutico , Transducción de Señal/efectos de los fármacos , Citrato de Sildenafil , Sulfonas/uso terapéutico , Tadalafilo , Resultado del Tratamiento , Vasodilatadores/efectos adversos , Vasodilatadores/farmacocinéticaRESUMEN
Moist wound care has been established as standard therapy for chronic wounds with impaired healing. Healing in acute wounds, in particular in minor superficial acute wounds - which indeed are much more numerous than chronic wounds - is often taken for granted because it is assumed that in those wounds normal phases of wound healing should run per se without any problems. But minor wounds such as small cuts, scraps or abrasions also need proper care to prevent complications, in particular infections. Local wound care with minor wounds consists of thorough cleansing with potable tap water or normal saline followed by the application of an appropriate dressing corresponding to the principles of moist wound treatment. In the treatment of smaller superficial wounds, it appears advisable to limit the choice of dressing to just a few products that fulfil the principles of moist wound management and are easy to use. Hydroactive colloid gels combining the attributes of hydrocolloids and hydrogels thus being appropriate for dry and exuding wounds appear especially suitable for this purpose - although there is still a lack of data from systematic studies on the effectiveness of these preparations.
Asunto(s)
Piel/lesiones , Cicatrización de Heridas/fisiología , Heridas y Lesiones/terapia , Vendajes , Cicatriz/prevención & control , Coloides , Humanos , Hidrogeles , Heridas y Lesiones/fisiopatologíaRESUMEN
Wound infections present a significant clinical challenge, impacting on patient morbidity and mortality, with significant economic implications. Silver-impregnated wound dressings have the potential to reduce both wound bioburden and healing time. The silver ion Ag+ is the active antimicrobial entity; it can interfere with thiol (-SH) groups and provoke the generation of reactive oxygen species (ROS), a major contributor to its antibacterial efficacy. Recently, silver nanoparticles have gained considerable interest in wound bioburden reduction and in anti-inflammation, as they can release Ag+ ions at a greater rate than bulk silver, by virtue of their large surface area. If released from dressings, they also have the potential to cross biological compartments. This review aims to consolidate recent findings as to the efficacy and safety of different formulations of silver used as an antiseptic agent in dressings, summarising the features of silver nanomaterials, with particular attention to the dose-dependencies for biological effects, highlighting the need for information on their uptake and potential biological effects.
Asunto(s)
Antiinfecciosos Locales/uso terapéutico , Vendajes , Nanopartículas del Metal/uso terapéutico , Plata/uso terapéutico , Heridas y Lesiones/terapia , Antiinfecciosos Locales/efectos adversos , Antiinfecciosos Locales/farmacocinética , Humanos , Nanopartículas del Metal/efectos adversos , Seguridad , Plata/efectos adversos , Plata/farmacocinéticaRESUMEN
Not only does wound infection and the release of pro-inflammatory modulators result in pain and delayed healing, but pain-related stress reduces the immune response to infection. Treatment of pain and infection should be equal priorites.
Asunto(s)
Dolor/etiología , Infección de Heridas/complicaciones , Vendajes , Humanos , Mediadores de Inflamación/inmunología , Evaluación en Enfermería , Dolor/diagnóstico , Dolor/prevención & control , Dimensión del Dolor , Prevalencia , Factores de Riesgo , Cuidados de la Piel/métodos , Cuidados de la Piel/enfermería , Estrés Psicológico/etiología , Estrés Psicológico/prevención & control , Cicatrización de Heridas , Infección de Heridas/diagnóstico , Infección de Heridas/epidemiología , Infección de Heridas/prevención & controlRESUMEN
The AGREE collaboration provides minimum quality standards for guidelines, yet none of the current wound-care guidelines acknowledge whether they fulfil these criteria. Only guidelines that comply with AGREE are likely to improve practice.
Asunto(s)
Guías de Práctica Clínica como Asunto/normas , Garantía de la Calidad de Atención de Salud , Heridas y Lesiones/terapia , HumanosRESUMEN
BACKGROUND: The reflux disease questionnaire (RDQ) is a short, patient-completed instrument. AIMS: To investigate the psychometric characteristics of the RDQ in patients with heartburn-predominant (HB) and non-heartburn predominant (NHB) dyspepsia. METHODS: HB (n = 388) and NHB (n = 733) patients were randomized to esomeprazole 40 mg daily or twice daily for 1 week, followed by 3 weeks of esomeprazole 40 mg daily. RESULTS: High factor loadings (0.78-0.86) supported the 'regurgitation' dimension of the RDQ. Overlapping factor loadings in the 'heartburn' and 'dyspepsia' dimensions suggested symptom overlap. All dimensions demonstrated high internal consistency (Cronbach's alpha: 0.79-0.90). Intra-class correlation coefficients over 4 weeks were good (0.66-0.85). The RDQ showed good responsiveness over 4 weeks of treatment, with high effect sizes (> or =0.80). Moderate or large symptom improvements were reported by 90% and 77% of HB and NHB patients, respectively, following treatment. Patients who responded to acid suppression also experienced symptom benefits in all RDQ dimensions. CONCLUSIONS: The RDQ is reliable, valid and responsive to change in HB and NHB patients. The symptom overlap is important but need not play a major role in determining treatment strategy as both patient groups benefited from proton pump inhibitor treatment.
Asunto(s)
Antiulcerosos/uso terapéutico , Dispepsia/tratamiento farmacológico , Esomeprazol/uso terapéutico , Reflujo Gastroesofágico/tratamiento farmacológico , Pirosis/tratamiento farmacológico , Encuestas y Cuestionarios/normas , Adulto , Canadá , Ácido Gástrico/metabolismo , Humanos , Masculino , PsicometríaRESUMEN
BACKGROUND: The prevalence of Barrett's oesophagus in patients undergoing gastroscopy may be influenced by possible referral bias. AIM: To present the prevalence of Barrett's oesophagus from the the Canadian Adult Dyspepsia Empirical Therapy Prompt Endoscopy study and to explore potential risk factors for its presence. METHODS: Patients had not been on treatment for dyspepsia for 2-4 weeks prior to endoscopy, which was performed within 10 working days of presentation. RESULTS: Barrett's oesophagus was endoscopically suspected in 53 of 1040 cases (5%) and histologically confirmed by the presence of intestinal metaplasia in 25 (2.4%). The prevalence of biopsy-proven Barrett's oesophagus was 4% in patients with dominant reflux-like symptoms. Sixty-four percent with confirmed Barrett's oesophagus had dominant reflux-like symptoms compared with 37% without Barrett's oesophagus. Barrett's oesophagus was more common in patients >50 years of age; 68% of cases were males. The mean duration of symptoms was 10 years, yet 16% had symptoms of <1-year duration. Endoscopic reflux oesophagitis was present in 68% of confirmed Barrett's oesophagus patients. CONCLUSIONS: Barrett's oesophagus is confirmed on biopsy in about half of endoscopically suspected Barrett's oesophagus patients. Barrett's oesophagus is more common in males, in those with dominant reflux-like symptoms, and in patients with a longer symptom history.
Asunto(s)
Esófago de Barrett/epidemiología , Dispepsia/epidemiología , Anciano , Esófago de Barrett/complicaciones , Esófago de Barrett/diagnóstico , Canadá/epidemiología , Estudios de Cohortes , Dispepsia/diagnóstico , Dispepsia/etiología , Esofagitis Péptica/diagnóstico , Esofagitis Péptica/epidemiología , Esofagitis Péptica/etiología , Esofagoscopía/métodos , Femenino , Reflujo Gastroesofágico/diagnóstico , Reflujo Gastroesofágico/epidemiología , Reflujo Gastroesofágico/etiología , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/diagnóstico , Infecciones por Helicobacter/epidemiología , Helicobacter pylori/aislamiento & purificación , Hernia Hiatal/diagnóstico , Hernia Hiatal/epidemiología , Hernia Hiatal/etiología , Humanos , Masculino , Persona de Mediana Edad , PrevalenciaRESUMEN
Peptide deformylase (PDF) is a prokaryotic metalloenzyme that is essential for bacterial growth but is not required by mammalian cells. Thus, it represents a selective and promising target for the development of new antibacterial agents. Since deformylase inhibitors have yet to be used clinically as antibacterial drugs, compounds targeting this enzyme should avoid cross-resistance with currently used antibacterial agents. The PDF enzyme is a ferrous ion-containing metallohydrolase, but a nickel-containing surrogate is routinely used in the laboratory for testing inhibitors due to its better stability. Enzymes from several bacterial species have been cloned and both their three-dimensional structures and co-crystal structures with bound inhibitor have been determined. As a metallo enzyme, PDF lends itself to the well-precedented mechanism-based rational drug design approach. Using structural and mechanistic information together with high throughput screening, several types of potent PDF inhibitors have been identified. PDF inhibitors identified to date share a common structural feature of a "chelator + peptidomimetic" scaffold. Although compounds with many different chelators inhibit the cell free enzyme, only compounds containing hydroxamic acid or N-formyl hydroxylamine exhibit appreciable antibacterial activity. Several lead inhibitors have demonstrated in vivo efficacy and an excellent safety profile. Two PDF inhibitors, VIC-104959 (LBM415) and BB-83698, have progressed to Phase I clinical trials. In this review, different PDF inhibitors are compared and their biological activities are discussed. Structure-activity relationships have been established and the implications of this work in the design of future PDF inhibitors are considered.
Asunto(s)
Amidohidrolasas/antagonistas & inhibidores , Antibacterianos/farmacología , Infecciones Bacterianas/tratamiento farmacológico , Inhibidores Enzimáticos/farmacología , Bacterias Gramnegativas/enzimología , Bacterias Grampositivas/enzimología , Amidohidrolasas/metabolismo , Animales , Antibacterianos/efectos adversos , Antibacterianos/química , Antibacterianos/uso terapéutico , Proteínas Bacterianas/antagonistas & inhibidores , Proteínas Bacterianas/metabolismo , Ensayos Clínicos Fase I como Asunto , Inhibidores Enzimáticos/efectos adversos , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/uso terapéutico , Bacterias Gramnegativas/efectos de los fármacos , Bacterias Grampositivas/efectos de los fármacos , Humanos , Pruebas de Sensibilidad Microbiana , Modelos Moleculares , Estructura Molecular , Relación Estructura-ActividadRESUMEN
BACKGROUND: There are few data on empiric, stepped therapy for heartburn relief or subsequent relapse in primary care. AIMS: To compare heartburn relief produced by a proton pump inhibitor-start or an H(2)-receptor antagonist-start with step-up therapy, as needed, followed by a treatment-free period to assess relapse. METHODS: Heartburn-dominant uninvestigated dyspepsia patients from 46 primary care centres were randomized to one of two active treatment strategies: omeprazole 20 mg daily (proton pump inhibitor-start) or ranitidine 150 mg bid (H2-receptor antagonist-start) for the first 4-8 weeks, stepping up to omeprazole 40 or 20 mg daily, respectively, for 4-8 weeks for persistent symptoms. Daily diaries documented heartburn relief (score < or = 3/7 on < or = of 7 prior days) and relapse (score > or = 4 on > or = 2 of 7 prior days). RESULTS: For 'proton pump inhibitor-start' (n = 196) vs. 'H2-receptor antagonist-start' (n = 194), respectively, heartburn relief occurred in 55.1% vs. 27.3% (P < 0.001) at 4 weeks and in 88.3% vs. 87.1% at 16 weeks. After therapy, 308 patients were heartburn-free (159 vs. 149); median times to relapse were 8 vs. 9 days and cumulative relapse rates were 78.6% vs. 75.8%, respectively. CONCLUSIONS: An empiric 'proton pump inhibitor-start' strategy relieves heartburn more effectively than an 'H2-receptor antagonist-start' strategy up to 12 weeks but has no effect on subsequent relapse, which is rapid in most patients.
Asunto(s)
Antiulcerosos/uso terapéutico , Dispepsia/tratamiento farmacológico , Pirosis/tratamiento farmacológico , Antagonistas de los Receptores H2 de la Histamina/uso terapéutico , Inhibidores de la Bomba de Protones , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antiulcerosos/administración & dosificación , Antiulcerosos/efectos adversos , Método Doble Ciego , Esquema de Medicación , Femenino , Antagonistas de los Receptores H2 de la Histamina/administración & dosificación , Antagonistas de los Receptores H2 de la Histamina/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Omeprazol/administración & dosificación , Omeprazol/efectos adversos , Omeprazol/uso terapéutico , Calidad de Vida , Ranitidina/administración & dosificación , Ranitidina/efectos adversos , Ranitidina/uso terapéutico , Recurrencia , Resultado del TratamientoRESUMEN
EACR-18 was the 18th biennial meeting of the European Association for Cancer Research (EACR). It attracted more than 700 delegates, providing a pivotal European forum for basic scientists, translational researchers and clinical oncologists alike. It covered most of the key areas and recent developments in cancer research. This Review presents a meeting report.
Asunto(s)
Investigación Biomédica , Neoplasias , Biosíntesis de Proteínas/genética , Europa (Continente) , Humanos , Neoplasias/genética , Neoplasias/terapiaRESUMEN
This review provides a summary of the European Association for Cancer Research Award Lecture, presented at the ECCO12 meeting in Copenhagen in September 2003. It describes what we have learnt about the mechanisms responsible for deregulating RNA polymerase III transcription in transformed cells. A network has been discovered of unanticipated links to key tumour suppressors and oncogenes. Novel functions have been revealed for RB, p53 and c-Myc, that may help explain their profound biological effects.
Asunto(s)
Neoplasias/genética , ARN Polimerasa III/genética , Transcripción Genética , División Celular , Tamaño de la Célula , Genes Supresores de Tumor , Humanos , Neoplasias/enzimología , Oncogenes , ARN Polimerasa III/antagonistas & inhibidores , Proteína de Retinoblastoma/metabolismo , Factores de Transcripción/antagonistas & inhibidores , Factores de Transcripción/metabolismoRESUMEN
Peptide deformylase (PDF), a metallohydrolase essential for bacterial growth, is an attractive target for use in the discovery of novel antibiotics. Focused chelator-based chemical libraries were constructed and screened for inhibition of enzymatic activity, inhibition of Staphylococcus aureus growth, and cytotoxicity. Positive compounds were selected based on the results of all three assays. VRC3375 [N-hydroxy-3-R-butyl-3-(2-S-(tert-butoxycarbonyl)-pyrrolidin-1-ylcarbonyl)propionamide] was identified as having the most favorable properties through an integrated combinatorial and medicinal chemistry effort. This compound is a potent PDF inhibitor with a K(i) of 0.24 nM against the Escherichia coli Ni(2+) enzyme, possesses activity against gram-positive and gram-negative bacterial pathogens, and has a low cytotoxicity. Mechanistic experiments demonstrate that the compound inhibits bacterial growth through PDF inhibition. Pharmacokinetic studies of this drug in mice indicate that VRC3375 is orally bioavailable and rapidly distributed among various tissues. VRC3375 has in vivo activity against S. aureus in a murine septicemia model, with 50% effective doses of 32, 17, and 21 mg/kg of body weight after dosing by intravenous (i.v.), subcutaneous (s.c.), and oral (p.o.) administration, respectively. In murine single-dose toxicity studies, no adverse effects were observed after dosing with more than 400 mg of VRC3375 per kg by i.v., p.o., or s.c. administration. The in vivo efficacy and low toxicity of VRC3375 suggest the potential for developing this class of compounds to be used in future antibacterial drugs.